Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People's Republic of China.
| Revenue | N/A |
| Net Income | N/A |
| Free Cash Flow | N/A |
| Book Value / Share | N/A |
| Total Liabilities | N/A |
| Total Equity | N/A |
| Debt / Equity | N/A |
| Current Ratio | N/A |
| Interest Coverage | N/A |
| Working Capital | N/A |
Core multiples and valuation signals — useful to compare vs peers.
| P/E (TTM) | N/A |
| Industry P/E | N/A |
| Forward P/E | N/A |
| P/B | N/A |
| Price / Sales | N/A |
| P / FCF | N/A |
| EV / EBITDA | N/A |
| Graham Number | N/A |
| DCF (placeholder) | — |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Net Margin | N/A |
| ROIC | N/A |
| Asset Turnover | N/A |
| RSI (14) | 83.23 |
| SMA 50 | 1.74 |
| SMA 200 | 1.39 |
| MACD | 0.06 |
| Signal | BULLISH |
| Name | Title |
|---|---|
| Dr. Jinzi Jason Wu Ph.D. | Founder, Chairman & CEO (1964) |
| Ms. Hejingdao Wu | Senior VP of Operations & Executive Director (1974) |
| Dr. Kristjan Sigurdur Gudmundsson | Senior Consultant & Head of Discovery (1968) |
| Dr. George Zhengzhi Hill | Senior Consultant & Chief Medical Advisor (1951) |
| Mr. John P. Gargiulo M.B.A. | Chief Business Officer (1960) |
| Mr. Ming Fai Chung CPA | Company Secretary (1980) |
No news available for this company.